Literature DB >> 23347194

HNA-1d: a new human neutrophil antigen located on Fcγ receptor IIIb associated with neonatal immune neutropenia.

Angelika Reil1, Ulrich J Sachs, Tania Siahanidou, Brigitte K Flesch, Juergen Bux.   

Abstract

BACKGROUND: Neonatal immune neutropenia (NIN) is a rare, but potentially life-threatening, disorder caused by maternal alloantibodies recognizing paternal neutrophil antigens on fetal cells. Alloantibodies directed against the human neutrophil alloantigen system (HNA)-1 located on Fcγ receptor IIIb (FcγRIIIb) are most frequently implicated in NIN. In this report, we describe two cases of NIN with alloantibodies against FcγRIIIb, which did not match one of the known HNA-1a, -1b, or -1c specificities, but define a new antigen, HNA-1d. STUDY DESIGN AND METHODS: Neutrophil-reactive antibodies were detected by agglutination, microscopic immunofluorescence, and monoclonal antibody (MoAb)-specific immobilization of neutrophil antigens (MAIGA) assay. For epitope mapping of FcγRIIIb-reactive antibodies, recombinant chimeric variants of FcγRIIIb were used in the MAIGA assay. Genotyping of FCGR3B was performed by allele-specific polymerase chain reaction.
RESULTS: Both mothers were typed FCGR3B*01+, *02-, *03+. Antibody screening revealed the presence of alloantibodies reactive with FcγRIIIb encoded by FCGR3B*02, but not with FcγRIIIb encoded by FCGR3B*03. MAIGA with recombinant, partly chimeric FcγRIIIb variants demonstrated that the antigen recognized by maternal antibodies is characterized by two amino acids, Ala78 and Asp82. Among the FCGR3B alleles, the sequence Ala78---Asn82 is exclusively encoded by FCGR3B *02.
CONCLUSION: A previously unrecognized second antigen, HNA-1d, is present on FcγRIIIb encoded by FCGR3B*02. This antigen is characterized by the sequence Ala78---Asn82. It appears that only individuals carrying the HNA-1c phenotype can form anti-HNA-1d alloantibodies. The HNA-1 system now consists of four antigens encoded by three alleles.
© 2013 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23347194     DOI: 10.1111/trf.12086

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  7 in total

1.  Molecular and Functional Characterization of Fcγ Receptor IIIb-Ligand Interaction: Implications for Neutrophil-Mediated Immune Mechanisms in Malaria.

Authors:  Ulrich J Sachs; Sentot Santoso; Piyapong Simtong; Amornrat V Romphruk; Annalena Traum; Monika Burg-Roderfeld; Gregor Bein; Konstantin Jakubowski; Andreas Dominik; Michael Theisen; Ikhlaq Hussain Kana
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

Review 2.  Immune neutropenias of infancy and childhood.

Authors:  Piero Farruggia
Journal:  World J Pediatr       Date:  2015-11-19       Impact factor: 2.764

Review 3.  Molecular Genetics of the Human Neutrophil Antigens.

Authors:  Brigitte Katharina Flesch; Angelika Reil
Journal:  Transfus Med Hemother       Date:  2018-08-17       Impact factor: 3.747

4.  Genotyping of human neutrophil antigens (HNA) from whole genome sequencing data.

Authors:  Hsueh-Ting Chu; Han Lin; Theresa Tsun-Hui Tsao; Chun-Fan Chang; William Wl Hsiao; Tze-Jung Yeh; Ching-Mao Chang; Yen-Wenn Liu; Tse-Yi Wang; Ko-Chun Yang; Tsung-Jui Chen; Jen-Chih Chen; Kuang-Chi Chen; Cheng-Yan Kao
Journal:  BMC Med Genomics       Date:  2013-09-12       Impact factor: 3.063

Review 5.  Neonatal Immune Incompatibilities between Newborn and Mother.

Authors:  Borros Arneth
Journal:  J Clin Med       Date:  2020-05-14       Impact factor: 4.241

Review 6.  Effect of Fc Receptor Genetic Diversity on HIV-1 Disease Pathogenesis.

Authors:  Daniel E Geraghty; Christian W Thorball; Jacques Fellay; Rasmi Thomas
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

Review 7.  Genetic Variation in Low-To-Medium-Affinity Fcγ Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine.

Authors:  Sietse Q Nagelkerke; David E Schmidt; Masja de Haas; Taco W Kuijpers
Journal:  Front Immunol       Date:  2019-10-03       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.